Candel Therapeutics: director Paul B Manning received 2,189 shares

What happened

• The Form 4 reports that Paul B Manning, a director, was granted 2,189 shares at $8.68 per share on Sep 30, 2026, for a total value of $18,992. The filing classifies the transaction as a derivative award (code A).

Key details

• Transaction date and price: Sep 30, 2026 at $8.68 per share.
• Shares owned after the transaction: not disclosed in the filing.
• Footnote F1 (from the filing): "This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant."
• Form 4 filed on Oct 2, 2026; the filing shows the transaction date as Sep 30, 2026.

Why it may matter

• The filing shows an award of shares delivered in lieu of quarterly cash payments; the underlying shares are fully vested at grant. This was an award, not a market purchase or sale. A filing does not show why the insider traded or why the company acted.